Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genscript Biotech Corp
(OP:
GNNSF
)
1.605
UNCHANGED
Last Price
Updated: 1:34 PM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
1.605
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
1.605
Today's Range
1.605 - 1.605
52wk Range
1.050 - 3.200
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation?
August 01, 2024
Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its...
Via
Benzinga
Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal
July 20, 2024
In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal.
Via
Talk Markets
Performance
YTD
-22.46%
-22.46%
1 Month
N/A
N/A
3 Month
+52.86%
+52.86%
6 Month
-19.43%
-19.43%
1 Year
-33.68%
-33.68%
More News
Read More
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
June 08, 2024
Via
Talk Markets
3 DNA Stocks to Buy for the Synthetic Biology Revolution
May 14, 2023
Via
InvestorPlace
The Next Big Disruptors? 3 Biotech Stocks Making Headlines.
February 17, 2023
Via
InvestorPlace
Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million
January 21, 2023
Via
Talk Markets
Three Pharma Stocks to Sell Before They Die
December 24, 2022
Via
InvestorPlace
Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact
December 10, 2022
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.